Unsettled
Executive Summary
Few industry executives believe the settlement of litigation between independent pharmacists and drug cpompanies itself will change company pricing practices; if anything, the court emphatically affirmed that differential pricing supports, rather than undermines, a competitive marketplace.
You may also be interested in...
Drug Firms Fear PBM ‘Discrimination’ Over List Price Reductions, Azar Tells Hearing
HHS Secretary Azar explains why companies have not voluntarily lowered prices as yet, despite President Trump’s recent comments. He also discussed using regulations to prohibit rebates.
A World Without Rebates: Is FDA’s Gottlieb Offering New Vision?
US FDA Commissioner Gottlieb suggests administrative action to prohibit drug rebates as a way to lower drug prices. His remarks may preview an upcoming proposal from President Trump and HHS Secretary Azar.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”